Hangzhou Diagens Biotechnology Co Ltd
Company Profile
Business description
Hangzhou Diagens Biotechnology Co Ltd and its subsidiaries are involved in the development and commercialisation of medical imaging artificial intelligence technologies and medical imaging equipment. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The majority of the company's revenue is derived from Technology Licensing, mainly in the Chinese mainland.
Contact
No. 609 Hongfeng Road
Room 101, Building 1
Donghu Sub-district
Linping District, Zhejiang
Hangzhou
CHNT: +86 4000680888
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
182
Stocks News & Analysis
stocks
Alphabet raises $80 billion for AI efforts
stocks
SpaceX: What investors need to know about its enormous upcoming IPO
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,017.20 | 3.10 | -0.03% |
| CAC 40 | 8,153.96 | 55.13 | -0.67% |
| DAX 40 | 24,818.76 | 305.41 | -1.22% |
| Dow JONES (US) | 50,999.30 | 308.49 | -0.60% |
| FTSE 100 | 10,349.23 | 24.28 | -0.23% |
| HKSE | 25,633.21 | 405.11 | -1.56% |
| NASDAQ | 26,910.60 | 183.30 | -0.68% |
| Nikkei 225 | 68,402.13 | 1,667.89 | 2.50% |
| NZX 50 Index | 13,115.08 | 55.63 | -0.42% |
| S&P 500 | 7,571.84 | 37.94 | -0.50% |
| S&P/ASX 200 | 8,785.70 | 5.90 | 0.07% |
| SSE Composite Index | 4,083.97 | 8.87 | 0.22% |